5421 results
Keyword Benazepril EG Remove keyword
-
List item
Veterinary medicine European public assessment report (EPAR): Fortekor Plus
benazepril hydrochloride, pimobendan, Dogs
Date of authorisation: 08/09/2015, Revision: 3, Authorised, Last updated: 06/11/2018substances, pimobendan and benazepril hydrochloride. It is only … same doses of pimobendan and benazepril hydrochloride given as separate … tablets (pimobendan 1.25 mg/benazepril hydrochloride 2.5 mg and … -
List item
Veterinary medicine European public assessment report (EPAR): Cardalis
benazepril hydrochloride, spironolactone, Dogs
Date of authorisation: 23/07/2012, Revision: 4, Authorised, Last updated: 10/12/2020benazepril hydrochloride / spironolacton … Cardalis, INN-benazepril spironolactone 7 Westferry … for the public Cardalis Benazepril hydrochloride / spironolactone … -
List item
Referral: Fortekor
benazepril hydrochloride, Article 34
Status: European Commission final decision, opinion/position date: 10/11/2011, EC decision date: 06/02/2012, Last updated: 11/03/2019Benazepril hydrochloride is a prodrug … to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective … medicinal product containing benazepril hydrochloride presented in … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): EGFR-cMET bispecific antibody
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002573-PIP01-19, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion, Solution for injection
Decision date: 16/08/2019, Last updated: 20/11/2019, Compliance check: XActive substance EGFR-cMET bispecific antibody Therapeutic … EGFR-cMET bispecific antibody … -
List item
Withdrawn application: Egranli
date of withdrawal: 04/11/2014, Initial authorisation, Last updated: 16/02/2015Egranli: Withdrawn application … Egranli, INN-balugrastim 30 … initial authorisation) Egranli balugrastim On 25 September … -
List item
Withdrawn application: Egrifta
date of withdrawal: 21/06/2012, Initial authorisation, Last updated: 18/07/2012Egrifta: Withdrawn application … authorisation application for Egrifta (tesamorelin) On 21 June … marketing authorisation for Egrifta, for the treatment of excess … -
List item
Human medicine European public assessment report (EPAR): Arepanrix
split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs., Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 23/03/2010,
, Revision: 1, Withdrawn, Last updated: 25/10/2011
strain (X-179A)*propagated in eggs. International non-proprietary … in the vaccine, such as egg or chicken protein, ovalbumin … protein, ovalbumin (a protein in egg white), formaldehyde and … -
List item
Human medicine European public assessment report (EPAR): Humenza
split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs., Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 08/06/2010,, Withdrawn, Last updated: 30/06/2011
strain (X-179A)*propagated in eggs. International non-proprietary … as ovalbumin (a protein in egg white egg or chicken proteins, neomycin … strain (X-179A)*propagated in eggs. … -
List item
Orphan designation: 20% Intravenous fat emulsion consisting of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection for: Treatment of poisoning by local anaesthetics
Date of first decision: 03/04/2017, Negative, Last updated: 15/05/2017of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25 … of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25 … of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25 … -
List item
Human medicine European public assessment report (EPAR): Daronrix
Whole virion, inactivated, containing antigen*: A/Vietnam/1194/2004 (H5N1)* produced in eggs, Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 21/03/2007,
, Withdrawn, Last updated: 02/07/2013
A/Vietnam/1194/2004 (H5N1)* produced in eggs International non-proprietary … in the vaccine, such as eggs, chicken protein or gentamicin … A/Vietnam/1194/2004 (H5N1)* produced in eggs … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Humenza, Split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), adjuvanted
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-000669-PIP01-09-M02, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension and emulsion for injection
Decision date: 04/01/2019, Last updated: 16/04/2019, Compliance check: Xstrain (X-179A)*propagated in eggs. … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Arepanrix, Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted), containing antigen equivalent to Influenza A/California/7/2009
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-000687-PIP01-09-M02, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension and emulsion for emulsion for injection
Decision date: 09/08/2010, Last updated: 07/10/2010, Compliance check: V, 12/12/2014strain (X-179A)*propagated in eggs. … -
List item
National expert: Adalheidur Eggertsdottir, Icelandic Medicines Agency (updated)
- Declaration of interests - 80.28 KB | PDF
- Curriculum Vitae - 18 KB | PDF
Vitae PERSONAL INFORMATION Adalheidur Eggertsdottir WORK EXPERIENCE April 2019 … Eggertsdottir 2020-12-29 Classified as … interests I, Adalheidur Eggertsdottir Organisation/Company: Icelandic … -
List item
National expert: Egle Daniuleviciute, Lithuania States Medicines Control Agency (updated)
- Declaration of interests - 79.82 KB | PDF
- Curriculum Vitae - 72.76 KB | PDF
vitae PERSONAL INFORMATION Egle Daniuleviciute WORK EXPERIENCE 2014–Present … 2 Curriculum vitae Egle Daniuleviciute – CTFG … declaration of interests I, EGL? DANIULEVI?I?T? Organisation/Company … -
List item
National expert: Iveta Eglite, Latvian State Agency of Medicines (updated)
- Declaration of interests - 79.76 KB | PDF
- Curriculum Vitae - 16.65 KB | PDF
Vitae PERSONAL INFORMATION Iveta Eglite WORK EXPERIENCE February … Eglite 2020-12-14 Classified as … declaration of interests I, Iveta Eglite Organisation/Company: Latvian … -
List item
National expert: Egberdina Botjes, European Medicines Agency (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 16.22 KB | PDF
Vitae PERSONAL INFORMATION Egberdina Botjes WORK EXPERIENCE January … declaration of interests I, Egberdina Botjes Organisation/Company … EMA website. Full Name: Egberdina (Erna) Botjes Bronsdijk Date … -
List item
National expert: Egidijus Morkunas, Lithuania States Medicines Control Agency (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 17.47 KB | PDF
Vitae PERSONAL INFORMATION Egidijus Morkunas WORK EXPERIENCE September … declaration of interests I, Egidijus Morkunas Organisation/Company … EMA website. Full Name: Egidijus Morkunas Date: 2020-12-29 For … -
List item
National expert: Egle Karinauske, Lithuania States Medicines Control Agency (updated)
- Declaration of interests - 79.77 KB | PDF
- Curriculum Vitae - 17.97 KB | PDF
Vitae PERSONAL INFORMATION Egle Karinauske WORK EXPERIENCE August … declaration of interests I, Egle Karinauske Organisation/Company … EMA website. Full Name: Egle Karinauske Date: 2020-12-15 For … -
List item
National expert: Egbert Flory, Paul-Ehrlich-Institute (updated)
- Declaration of interests - 80.02 KB | PDF
- Curriculum Vitae - 22.1 KB | PDF
Vitae PERSONAL INFORMATION Egbert Flory WORK EXPERIENCE … declaration of interests I, Egbert Flory Organisation/Company … EMA website. Full Name: Egbert Flory Date: 2021-01-11 For … -
List item
National expert: Erlend Johannessen Egeland, Norwegian Medicines Agency (updated)
- Declaration of interests - 79.77 KB | PDF
- Curriculum Vitae - 17.7 KB | PDF
INFORMATION Erlend Johannessen Egeland WORK EXPERIENCE August … transplantation Renal failure Publications 1 Egeland EJ, Witczak BJ, Zaré HK … 2020; 108(4): 866-873 2. Egeland EJ, Reisæter AV, Robertsen … -
List item
National expert: Susanne Mueller-Egert, Paul-Ehrlich-Institute (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 17 KB | PDF
INFORMATION Susanne Mueller-Egert WORK EXPERIENCE February … Mueller-Egert 2020-12-07 Classified as … interests I, Susanne Mueller-Egert Organisation/Company: Paul-Ehrlich-Institute Country … -
List item
National expert: Bjoern Egil Olsen, Norwegian Medicines Agency (updated)
- Declaration of interests - 79.76 KB | PDF
- Curriculum Vitae - 17.18 KB | PDF
Vitae PERSONAL INFORMATION Bjoern Egil Olsen WORK EXPERIENCE March … declaration of interests I, Bjoern Egil Olsen Organisation/Company … website. Full Name: Bjørn Egil Olsen Date: 2020-12-09 For … -
List item
National expert: Hedvig Marie Egeland Nordeng, European Medicines Agency (updated)
- Declaration of interests - 80.23 KB | PDF
- Curriculum Vitae - 20.85 KB | PDF
INFORMATION Hedvig Marie Egeland Nordeng WORK EXPERIENCE January … interests I, Hedvig Marie Egeland Nordeng Organisation/Company … Hedvig Marie Egeland Nordeng … -
List item
Referral: Renin-angiotensin-system (RAS)-acting agents
captopril, imidapril, zofenopril, candesartan, delapril, telmisartan, aliskiren, moexipril, enalapril, valsartan, fosinopril, irbesartan, perindopril, quinapril, ramipril, eprosartan, olmesartan, trandolapril, losartan, azilsartan, lisinopril, spirapril, benazepril, cilazapril, associated names: Tolucombi, Telmisartan Teva, Telmisartan Teva Pharma, Tolura, Onduarp, Twynsta, Actelsar HCT, Kinzalkomb, MicardisPlus, PritorPlus, Copalia HCT, Dafiro HCT, Exforge HCT, Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Edarbi, Ipreziv, Aprovel, Ifirmasta (previously Irbesartan Krka), Irbesartan Teva, Irbesartan Zentiva (previously Irbesartan Winthrop), Karvea, Sabervel, CoAprovel, Ifirmacombi, Irbesartan/Hydrochlorothiazide Teva, Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), Karvezide, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Micardis, Pritor, Telmisartan Actavis, Article 31 referrals
Status: European Commission final decision, opinion/position date: 22/05/2014, EC decision date: 04/09/2014, Last updated: 08/10/2014Actavis captopril imidapril zofenopril candesartan delapril telmisartan aliskiren moexipril enalapril valsartan fosinopril irbesartan perindopril quinapril ramipril eprosartan olmesartan trandolapril losartan azilsartan lisinopril spirapril benazepril cilazapril captopril, imidapril … -
List item
Press release: Ferrer Internacional, S.A. withdraws its marketing authorisation application for Egrifta (tesamorelin)
Last updated: 26/06/2012authorisation application for Egrifta (tesamorelin … authorisation application for Egrifta (tesamorelin … authorisation application for Egrifta (tesamorelin) The European …